Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET-CT, there are some settings in which ot

PET-CT is increasingly being employed in the diagnosis of both oncological and non-oncological patients, yet nuclear medicine physicians may have only limited p

This pocket book explains the significant and well-documented impact that PET/CT can have on the management of prostate cancer through the provision of high-qua

PET and PET-CT in Oncology describes the principles of positron emission tomography and is a useful resource for incorporating the technique in clinical practic

Fluorodeoxyglucose (FDG) has proven benefits as a positron emission tomography (PET) radiopharmaceutical in oncology.